Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morepen LaboratoriesNSE:MOREPENLAB +0.43%72 Cash Ratio is 0.22 as of Mar. 2026, which is 450% above its 10-year median of 0.04. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 72/100 and a GF Value™ of ₹50.12 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 977 Drug Manufacturers companies, Morepen Laboratories ranks worse than 74.1% on this metric.
Morepen Laboratories has a Cash Ratio of 0.22. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Morepen Laboratories's Cash Ratio or its related term are showing as below:
NSE:MOREPENLAB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.22
Current: 0.22
During the past 13 years, Morepen Laboratories's highest Cash Ratio was 0.22. The lowest was 0.02. And the median was 0.04.
NSE:MOREPENLAB's Cash Ratio is ranked worse than 74.1% of 977
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:MOREPENLAB: 0.22
Morepen Laboratories (NSE:MOREPENLAB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Morepen Laboratories Cash Ratio Related Terms
Morepen Laboratories Cash Ratio Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a Cash Ratio of 0.22 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Morepen Laboratories and its competitors. This is 450% above median its historical median of 0.04. Over the past decade, Morepen Laboratories' Cash Ratio has ranged from 0.02 to 0.22. According to the industry distribution chart, Morepen Laboratories ranks #724 out of 977 companies in the Drug Manufacturers industry, placing it in the top 74.1%.
Is Morepen Laboratories' Cash Ratio too high?
Morepen Laboratories' current Cash Ratio of 0.22 is 450% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.22. The Drug Manufacturers industry median Cash Ratio is 0.61. Morepen Laboratories' value of 0.22 is 63.9% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #724 out of 977 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Cash Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #724 out of 977 companies for Cash Ratio. This places Morepen Laboratories in the lower half of its industry. The industry median Cash Ratio is 0.61. Morepen Laboratories' value of 0.22 is 63.9% below this benchmark. Historically, Morepen Laboratories' own Cash Ratio has ranged from 0.02 to 0.22 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.61, Morepen Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Cash Ratio of 0.22 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Cash Ratio is 0.22, which is 450% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹50.12, compared to a current price of ₹62.56 — trading 24.8% above its estimated fair value. The current Cash Ratio is 0.22, which is 450% above median its 10-year median of 0.04 and 63.9% below the Drug Manufacturers industry median of 0.61. Morepen Laboratories' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Cash Ratio is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹62.56 is trading 24.8% above its estimated GF Value™ of ₹50.12.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Cash Ratio: 0.22 (450% above median its 10-year median of 0.04)
GF Value™: ₹50.12 vs. price of ₹62.56 (24.8% above fair value)
Industry Position: 63.9% below the Drug Manufacturers median (#724 of 977)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
72GF Score
Get the complete analysis for NSE:MOREPENLAB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
